The grant marks the first time the company receives direct funding as principal investigator in a research study.
Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce that it has received a $1 million dollar grant from a consortium of investors, to strengthen the current ...